Aptevo Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
For the nine months, net loss was USD 11.51 million compared to net income of USD 12.67 million a year ago. Basic loss per share from continuing operations was USD 60.7199 compared to basic earnings per share from continuing operations of USD 106.9199 a year ago. Diluted loss per share from continuing operations was USD 60.7199 compared to diluted earnings per share from continuing operations of USD 106.9199 a year ago. Basic loss per share was USD 56.3199 compared to basic earnings per share of USD 110.8799 a year ago. Diluted loss per share was USD 56.3199 compared to diluted earnings per share of USD 110.8799 a year ago.